**Supplement 2:** Reference list of full text articles excluded and ongoing/unpublished studies

Aman M, Rettiganti M, Nagaraja HN, et al. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. *J Child Adolesc Psychopharmacol.* 2015;25: 482-493.

Bailly D. Pharmacological treatment of bipolar disorder in children and adolescents. *Encephale.* 2017;43: 254-258.

Beasley CM, Sutton VK, Hamilton SH, et al. Olanzapine Relapse Prevention Study Group: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. *J Clin Psychopharmacol.* 2003;23:582-594.

Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. *J Clin Psychiatry.* 2010;71: 130-137.

Correll C, Nyilas M, Aurang C, et al. Similar efficacy results in short- and long-term studies of aripiprazole in adolescents (ages 15-17) and adults with schizophrenia. *Eur Arch of Psychiatry Clin Neurosci.* 2009;259: S81. (POSTER)

Correll CU, Kohegyi E, Zhao C, et al. (Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia: A randomized, double-blind, placebo-controlled trial. *Neuropsychopharmacology.* 2014;39: (POSTER)

Daglas R, Cotton SM, Allott K, et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12-month follow-up study. *Eur Psychiatry*. 2016;31: 20-28.

Davis LL, Frazier EC, Williford RB, et al. Long-term pharmacotherapy for post-traumatic stress disorder. *CNS drugs*. 2006;20: 465-476.

Diaz-Caneja CM, Moreno C, Llorente C, et al. Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder. *J Child Psychol Psychiatry.* 2014;55: 959-980.

Dinca O, Paul M, Spencer NJ. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. *J Psychopharmacol*. 2005;19: 521-532.

Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. *Schizophr Res*. 2007;89: 129-139.

EudraCT 2012-004546-15 (unpublished) Assessment of incidence of adverse events in a naive paediatric population treated with an antipsychotic drug over 12 months follow-up. EU Clinical Trials Register. Available at: www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004546-15+.

EudraCT 2011-000567-26 (unpublished) A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. EU Clinical Trials Register. Available at:www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000567-26.

Fleischhaker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia*. Int Clin Psychopharmacol.* 2013;28: 171-176.

Forbes A, Nyilas M, Johnson B, et al. Long-term efficacy and safety of aripiprazole in children and adolescents with mania. *Eur Neuropsychopharmacol.* 2008;18: (POSTER)

Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. *Eur Neuropsychopharmacol*. 2011;21: 621-645.

Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. *J Child Adolesc Psychopharmacol.* 2001;11: 229-238.

Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. *J Child Adolesc Psychopharmacol*. 2005;15: 885-892.

Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children, adolescents and adults with mental. *J Autism Dev Disord*. 2006;36: 401-411.

Hirsch and Pringsheim T Aripiprazole for autism spectrum disorders (ASD). *Cochrane Database Syst Rev* Issue 6. 2016;Art. No. CD009043.

Hui CL, Wong GH, Tang JY, et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. *Schizophr Res.* 2013;150: 297-302.

ISRCTN80567433 (unpublished) A randomised controlled trial of antipsychotic medication in comparison to psychological intervention and a combined treatment in children and young people with first episode psychosis: a feasibility study. ISRCTN Registry. Available at: <http://isrctn.com/ISRCTN80567433>.

ISRCTN95429815 (unpublished) Risperidone in children and adolescents with aggressive behaviour. ISRCTN Registry. Available at: <https://doi.org/10.1186/ISRCTN95429815>.

ISRCTN95609637 (unpublished) Relapse prevention in children and adolescents with aggressive behaviour problems treated with risperidone: Randomised controlled trial, for Conduct disorder /Oppositional Defiant Disorder. ISRCTN Registry. Available at: <https://doi.org/10.1186/ISRCTN95609637>.

ISRCTN21681959 (unpublished) Effective treatment of adolescents with aggression problems in clinical and non-clinical settings. ISRCTN Registry. Available at: <https://doi.org/10.1186/ISRCTN21681959>.

Jesner O, Aref-Adib M, Coven E. Risperidone for autism spectrum disorder. *Cochrane Database Syst Rev.* 2007;Issue 1. Art. No: CD005040.

Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. *J Clin Psychiatry.* 2011;72: 349-355.

Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. *Schizophr Bull*. 2007;33: 1082-1083.

Kongsakon R, Trinidad-Oñate P, Chaudhry HR, et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. *J Med Assoc Thai*. 2006;89: 1157-1170.

Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2005;44: 213-235.

Kumar A, Datta SS, Wright SD, et al. Atypical antipsychotics for psychosis in adolescents. *Cochrane Database Syst Rev.* 2013;Issue 10. Art. No: CD009582.

Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. *Depress Anxiety*. 2010;27: 964-976.

Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. *Cochrane Database Syst Rev*. 2017;Issue 8; Art. No: CD008559.

Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. *Bipolar Disord*. 2009;11: 827-839.

Malone RP, Maislin, G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. *J Am Acad Child Adolesc Psychiatry*. 2002;41: 140-147.

Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in paediatric patients with autistic disorder: a 52-week, open-label, multicenter study. *J Clin Psychiatry*. 2011;72: 1270-1276.

Masi G, Milone A, Veltri S, et al. Use of quetiapine in children and adolescents. *Paediatr Drugs*. 2015;17: 125-140.

NCT01119014 (unpublished) Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA). *ClinicalTrials.gov* ID: NCT01119014. Available at: [www.clinicaltrials.gov/ct2/show/NCT01119014](http://www.clinicaltrials.gov/ct2/show/NCT01119014).

NCT03448575 (Unpublished) Safer Use of Antipsychotics in Youth SUAY. *ClinicalTrials.gov* ID: NCT03448575. (Available at: <https://clinicaltrials.gov/show/NCT03448575>.

NL3070 (onging) A study to investigate efficacy, safety and tolerability of a medicin (risperidone) in treatment of aggression in children and adolescents. *Netherlands Trial Register* Available at: www.trialregister.nl/trial/3070

Pae CU, Kim TS, Kim JJ, et al. Long-term treatment of adjunctive quetiapine for bipolar mania. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005;29: 763-766.

Peruzzolo TL, Tramontina S, Rohde LA, et al. Pharmacotherapy of bipolar disorder in children and adolescents: an update. *Braz J Psychiatry*. 2013;35: 393-405.

Purdon SE, Woodward N, Lindborg SR, et al. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. *Psychopharmacology.* 2003;169: 390-397.

Reyes M, Olah R, Csaba K, et al. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. *Eur Child Adolesc Psychiatry*. 2006;15: 97-104.

Robinson DG, Gallego JA, John M, et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes*. Schizophr Bull*. 2015;41: 1227-1236.

Rui Q, Wang Y, Liang S, et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;53: 45-53.

RUPP (Research Units on Paediatric Psychopharmacology Autism Network). Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. *Am J Psychiatry*. 2005;162: 1361-1369.

Savitz AJ, Lane R, Nuamah I, et al. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. *J Am Acad Child Adolesc Psychiatry*. 2015;54: 126-137.

Sheehan DV, Svedsäter H, Locklear JC, et al. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data on a randomized-withdrawal, placebo-controlled maintenance study. *J Affect Disord*. 2013;151: 906-913.

Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. *J Am Acad Child Adolesc Psychiatry*. 2007;46: 1349-1356.

Texeira EH, Jacintho A, Celeri HV, et al. Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations. *Trends Psychiatry Psychother*. 2013;35: 151-159.

Thomas T, Stansifer L, Findling RL. Psychopharmacology of paediatric bipolar disorders in children and adolescents. *Pediatr Clin North Am*. 2011;58: 173.

Tiffin PA, WelshP. Practitioner Review: Schizophrenia spectrum disorders and the at risk mental state for psychosis in children and adolescents – evidence-based management approaches. *J Child Psychol Psychiatry*. 2013;54: 1155-1175.

Vitiello B, Correll C, Van Z-B, et al. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. *Eur Neuropsychopharmacol*. 2009;19: 629-635.

Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. *J Child Adolesc Psychopharmacol*. 2000;10: 79-90.